Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCH | P24723 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20242350 | 1.00 | FAAH (0.43) | FAAHOPRL1PRKD3PRKCGPRKCB | |
| SCHEMBL8203469 | 0.99 | OPRL1 (0.43) | FAAHOPRL1TDP1POLB | |
| SCHEMBL7562309 | 0.99 | OPRL1 (0.43) | FAAHOPRL1TDP1POLB | |
| SCHEMBL13054036 | 0.99 | OPRL1 (0.43) | FAAHOPRL1TDP1POLB | |
| SCHEMBL20241591 | 0.93 | FAAH (0.39) | FAAHOPRL1TDP1 | |
| SCHEMBL21528393 | 0.93 | FAAH (0.39) | FAAHOPRL1TDP1 | |
| SCHEMBL21528433 | 0.90 | HDAC8 (0.41) | FAAHOPRL1 | |
| SCHEMBL20241410 | 0.90 | HDAC8 (0.41) | FAAHOPRL1 | |
| SCHEMBL20242089 | 0.90 | FAAH (0.41) | FAAHTDP1 | |
| SCHEMBL20241402 | 0.90 | FAAH (0.41) | FAAHTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-06-30 | — | — | US | claimed |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | claimed |
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696639-B2 | Heterocyclic compounds as HIV protease inhibitors | PREP, SERPINB1, PEPD | FAAH 629/4885OPRL1 3661/4885PRKD3 3502/4885 |
| US-20190337902-A1 | HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS | PREP, SERPINB1, PEPD | FAAH 629/4885OPRL1 3661/4885PRKD3 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.